ArticleNatural products and bioprospecting2025
Inhibitory effects of corylin derived from aerial part of Pueraria lobata on melanin synthesis and potential applications in skin whitening and photoaging management.
Article in Natural products and bioprospecting, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Green ultrasound‑assisted deep eutectic solvent extraction of flavonoid enzyme inhibitors fromJournal of enzyme inhibition and medicinal chemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to investigate the potential of corylin, a bioactive compound isolated from the aerial part of Pueraria lobata, as a novel skin-whitening agent. Specifically, the research sought to evaluate its effects on melanin synthesis, understand its underlying mechanisms, and validate its efficacy in mitigating hyperpigmentation.
methodsBioactive compound was isolated from Pueraria lobata through a systematic fractionation process involving activated carbon pigment removal, sequential solvent extraction, and resin-based chromatography. It was shown to inhibit melanin synthesis by targeting tyrosinase activation and modulating key signaling pathways. Its efficacy in reducing melanin production was validated through cellular assays and a UVB-stimulated 3D human skin model, highlighting its potential as a skin-whitening agent.
resultsThrough fractionation, the bioactive compound was identified as corylin, which reduced melanin content and tyrosinase activity without cytotoxicity, modulated signaling pathways to downregulate MITF and melanogenic enzymes, and inhibited α-glucosidase, disrupted glycosylation. In a UVB-stimulated 3D skin model, it effectively decreased melanin production, confirming its potential to mitigate hyperpigmentation.
conclusionCorylin is a promising candidate for skin-whitening applications, effectively mitigating hyperpigmentation by targeting multiple stages of melanin synthesis, including enzymatic activity and regulatory pathways. Further clinical studies are needed to confirm its safety and therapeutic potential for dermatological use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.